Company:  ADAMAS PHARMACEUTICALS IN ... (ADMS)
Form Type:  4
Filing Date:  11/8/2019 
CIK:  0001328143 
Address:  1900 POWELL ST., SUITE 1000 
City, State, Zip:  EMERYVILLE, California 94608 
Telephone:  510-450-3554 
Fiscal Year:  12/31 
Last Trade
Last Trade: 
$4.76  
Change: 
0.15 (3.25%)  
Trade Time: 
Sep 18  
Market Cap: 
$134.62M
Trade ADMS now with

© 2020  
Description of Business
At Adamas Pharmaceuticals, Inc., our purpose is to make everyday life significantly better for people affected by neurological diseases. We are turning this purpose into reality by combining our proven expertise in discovery, development and commercialization with our passion for improving lives. We believe our medicines should be clinically differentiated and provide a meaningful benefit to patients. With one partnered product and a commercial medicine, we are focused on growing a portfolio of therapies to reduce the burden of neurological diseases on patients, caregivers, and society. Our portfolio includes: Approved Product: *GOCOVRI® (amantadine) extended release capsules, is the first and only FDA-approved medication indicated for the treatment of dyskinesia in patients with Parkinson's disease receiving levodopa-based therapy, with or without concomitant dopaminergic medications.
Register and access this filing in:     
  FORM 4
    NAME AND TITLE
    NON DERIVATIVE SECURITIES
    DERIVATIVE SECURITIES
    EXPLANATIONS AND REMARKS
    REPORTING OWNERS
    SIGNATURES
  EXHIBIT 24.4 878790
    POWER OF ATTORNEY